Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merck’s Geographic Footprint Grows A Size (Or Two) With Schering Buy

This article was originally published in The Pink Sheet Daily

Executive Summary

Merck’s international sales will more than double to $25 billion with the acquisition of Schering-Plough.

You may also be interested in...

Merck Not Feeling Mega-Merger Mania Even As Pharma Sales Decline

Patent expiries for five products drag down revenue, but biotech deals and pipeline building remain Merck’s strategy, CEO Frazier says.

Merck/Schering: The Next Wave Of Consolidation

$41.1 bil. acquisition will create a cardiovascular powerhouse, buffer Merck against patent expirations of Singulair, Cozaar/Hyzaar and generate $3.5 bil in savings.

Schering-Plough Makes Its Move, Snapping Up Organon For $14.4 Billion

After much talk of a major acquisition, Schering buys the Organon pharmaceutical and animal health business of Akzo Nobel.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts